What's breaking now, across thousands of outlets.
Runaway applied behavior analysis spending exposes the moral hazard at the heart of Medicaid’s financing architecture.
We haven't written up this one. The Hill has the full story — the link below goes straight to it.
For nearly as long as they've been approved for diabetes and weight loss, GLP-1 drugs have captured the public imagination as a possible solution to diseases far beyond metabolic disorders.
A new study identifies a stable, brain-derived RNA molecule in the bloodstream that accurately predicts whether a patient will respond to common SSRI antidepressants, potentially saving months of…
Plus more from Baxter and United Therapeutics. Sanofi starts construction of an insulin factory: Sanofi has broken ground on a new 36,000-square-meter manufacturing facility at its site in Frankfurt…
Speaking on Channels Television’s The Morning Brief on Thursday, Mr Kaseya said he was familiar with the political dynamics across Africa, particularly in West Africa, and had been engaging leaders…
AbbVie unwrapped a Phase 3 success on Thursday for an experimental drug designed to treat a debilitating skin disease. In the trial, AbbVie’s IL-1α and IL-1β inhibitor lutikizumab improved patient…
